SCHEMBL4637813

SCHEMBL4637813

O=C(C#Cc1ccccc1Cl)c1nnn(Cc2cc(C(F)(F)F)cc(C(F)(F)F)c2)c1-c1ccncc1

nearest known ligand 0.39

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
IDH1 O75874 1/20 0.39
GRM2 Q14416 2/20 0.38
ALDH1A1 P00352 2/20 0.38
GAA P10253 1/20 0.38
PTGDR2 Q9Y5Y4 1/20 0.38
CYP19A1 P11511 4/20 0.37
TSHR P16473 2/20 0.37
USP2 O75604 2/20 0.36
CYP3A4 P08684 2/20 0.36
HIF1A Q16665 1/20 0.36
CYP2D6 P10635 1/20 0.36
SMN1; SMN2 Q16637 1/20 0.36
GPBAR1 Q8TDU6 3/20 0.35
AKR1C3 P42330 1/20 0.35
AKR1C2 P52895 1/20 0.35
ADORA3 P0DMS8 1/20 0.35
PTGER4 P35408 1/20 0.34
HTT P42858 1/20 0.34
L3MBTL1 Q9Y468 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4638053 0.94 ALDH1A1 (0.44) IDH1GRM2ALDH1A1GAAPTGDR2
SCHEMBL4707915 0.91 IDH1 (0.48) IDH1GRM2ALDH1A1GAAPTGDR2
SCHEMBL4637949 0.90 IDH1 (0.39) IDH1GRM2ALDH1A1GAAPTGDR2
SCHEMBL4638508 0.88 CYP19A1 (0.42) ALDH1A1CYP19A1TSHRCYP3A4HIF1A
SCHEMBL4637988 0.87 PTGDR2 (0.40) GRM2ALDH1A1GAAPTGDR2SMN1; SMN2
SCHEMBL4637887 0.86 USP2 (0.36) IDH1GRM2PTGDR2TSHRUSP2
SCHEMBL4637714 0.86 IDH1 (0.54) IDH1GRM2ALDH1A1PTGDR2CYP19A1
SCHEMBL4638554 0.84 CCR1 (0.39) GRM2ALDH1A1GAAPTGDR2SMN1; SMN2
SCHEMBL4637753 0.84 IDH1 (0.47) IDH1GRM2ALDH1A1PTGDR2CYP19A1
SCHEMBL4637824 0.84 ALDH1A1 (0.44) GRM2ALDH1A1GAAPTGDR2CYP19A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1501808-B1 TACHYKININ RECEPTOR ANTAGONISTS LILLY CO ELI (US) 2008-07-02 EP disclosed
EP-1501809-B1 TRIAZOLE DERIVATIVES AS TACHYKININ RECEPTOR ANTAGONISTS LILLY CO ELI (US) 2008-01-16 EP disclosed
US-7179804-B2 Tachykinin receptor antagonists ELI LILLY AND COMPANY (US) 2007-02-20 US disclosed
US-20050239776-A1 Tachykinin receptor antagonists ELI LILLY AND COMPANY (US) 2005-10-27 US disclosed
EP-1501808-A1 TACHYKININ RECEPTOR ANTAGONISTS ELI LILLY AND COMPANY (US) 2005-02-02 EP disclosed
WO-2003091227-A1 TACHYKININ RECEPTOR ANTAGONISTS ELI LILLY AND COMPANY (US) 2003-11-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050239776-A1 Tachykinin receptor antagonists TACR2, TACR1, PROKR1 IDH1 4314/4885GRM2 1240/4885ALDH1A1 1988/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.